Author: admin

Author: admin

Mr. Y. Mark Xu, Chairman of Xynomic Pharma Presented at the BioCentury China Healthcare Summit 2018
Image 11/19/2018 Uncategorized admin

China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China Healthcare Summit asked how the nation would build the “Bridge to Innovation.” In 2018, we examine how China is now actually
Details

Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018.
Image 11/07/2018 Uncategorized admin

Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018. Mr. Xu will present at 12:55 pm on Tuesday, November 13, 2018 at Ballroom I, 5th Floor, Jing An Shangri-La Hotel, Shanghai, China. BioCentury and BayHelix Present: The 5th China
Details

Y. Mark Xu talks with CGTN (China Global TV Network)
Image 10/26/2018 Uncategorized admin

Mark Xu, Founder, Chairman, Chief Executive Officer and President of Xynomic talks with CGTN “The Point with Liu Xin” and provides insight regarding the current trend of the price of cancer drugs in China. “The Point with Liu Xin” is an opinion program on CGTN (China Global Television Network) that explores news stories making headlines
Details

Bison Capital Acquisition Corp. and Xynomic Pharmaceuticals, Inc. Announce Signing of Definitive Merger Agreement
Image 09/29/2018 Uncategorized admin

NEW YORK, NY and SHANGHAI, China, Sept. 12, 2018 (GLOBE NEWSWIRE) –– Bison Capital Acquisition Corp. (“BCAC”, NASDAQ: BCAC) and Xynomic Pharmaceuticals, Inc. (“Xynomic”), a U.S.-China clinical stage innovative oncology drug development company, today jointly announced that they have signed a definitive merger agreement. Upon completion of the merger, Xynomic will become a wholly-owned subsidiary
Details

Xynomic Privacy Shield Data Privacy Statement
09/10/2018 Uncategorized admin

Privacy Shield Compliant Privacy Policy Xynomic Pharmaceuticals, Inc. (“Xynomic”) participates in the Privacy Shield, detailed information of which can be found at https://www.privacyshield.gov/welcome.  Xynomic adheres to each of the Privacy Shield Principles and is committed to subjecting to the Principles all personal information received from the EU in reliance on the EU-U.S. Privacy Shield Framework.
Details

Mark Xu ( Chairman and CEO of Xynomic ) Invited to Participate in JP Morgan Healthcare Conference
01/04/2018 Uncategorized admin

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

Xynomic Pharma Initiates Ph 1/2 Trial Combining Abexinostat with Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)
12/03/2017 Uncategorized admin

CHEYENNE, Wyo., Dec. 1, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it will initiate a Ph 1/2 trial, in collaboration with Janssen R&D, LLC (Janssen Pharmaceutical Companies of Johnson & Johnson, hereafter Janssen) and Memorial Sloan Kettering Cancer Center (MSK), to combine Abexinostat with Ibrutinib against r/r DLBCL
Details

Xynomic Pharma Acquires Global Rights of Boehringer Ingelheim’s BI 882370, a Novel and Potent RAF Inhibitor against Solid Tumors
11/07/2017 Uncategorized admin

CHEYENNE, Wyo., Oct. 30, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim, a top-20 global pharmaceutical company.  Under the terms of the agreement Xynomic will pay upfront, milestone and
Details

Xynonic Invited to Present at the Prestigious Berstein China Oncology Day in Hong Kong on June 21
05/29/2017 Uncategorized admin

Mr. Y. Mark Xu, Chairman, CEO and President, has been invited to speak at this high profile conference. Other presenting companies include Roche, Sanofi, Hengrui and Sino Biopharm. The venue is Mandarin Oriental Hotel, Hong Kong. This conference is expected to draw attendance of over 100 leading Asian institutional investors and high net worth individuals.

Xynomic Pharma and UCSF Entered Strategic Partnership in Conducting a Phase 2/3 Trial of Abexinostat against Renal Cell Carcinoma
05/26/2017 Uncategorized admin

CHEYENNE, Wyo., May 22, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco (“UCSF”) to conduct PAX Study, a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally
Details